NEJM publishes study evaluating the use of semaglutide to assist people with weight loss. Not “game-changing” but another positive step forward for evidenced-based treatment to help people with #Overweight or #Obesity.

Medical Mythbusting Commentary for February 16, 2021

Reference:Last week the NEJM published a study concluding “In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.”

A follow up editorial provides some perspective.

Bitnami